13D Filing: Versant Venture Capital IV, L.P. and Crispr Therapeutics AG (CRSP)

Published on September 18, 2017 at 12:06 pm by Insider Monkey Staff in Hedge Funds

Page 1 of 18

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Versant Venture Capital IV	2,736,032	0	2,736,032	0	2,736,032	6.74%
Versant Side Fund IV	16,224	0	16,224	0	16,224	0.04%
Versant Ventures IV	0	2,752,256	0	2,752,256	2,752,256	6.78%
Versant Venture Capital V	1,629,204	0	1,629,204	0	1,629,204	4.01%
Versant Affiliates Fund V	47,801	0	47,801	0	47,801	0.12%
Versant Ophthalmic Affiliates Fund I	52,987	0	52,987	0	52,987	0.13%
Versant Ventures V	0	1,729,992	0	1,729,992	1,729,992	4.26%
Versant Venture Capital V (Canada)	123,994	0	123,994	0	123,994	0.31%
Versant Ventures V GP-GP (Canada), Inc	0	123,994	0	123,994	123,994	0.31%
Versant Ventures V (Canada)	0	123,994	0	123,994	123,994	0.31%

Page 1 of 18 – SEC Filing

	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549

	SCHEDULE 13D

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

TO RULE 13d-2(a)

(Amendment No. 1)*

CRISPR THERAPEUTICS AG

(Name of Issuer)

Common Stock, par value CHF 0.03 per share

(Title of Class of Securities)

H17182108

(CUSIP Number)

Versant Ventures IV, LLC

Robin L. Praeger

One Sansome Street, Suite 3630

San Francisco, CA 94104

415-801-8100

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September 5, 2017

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Follow Crispr Therapeutics AgFollow Crispr Therapeutics Ag

Page 1 of 18

Next >>